AnaptysBio (ANAB) 2025 Conference September 03, 2025 08:00 AM ET Company ParticipantsPrakhar Agrawal - Managing DirectorDaniel Faga - President & CEOPrakhar AgrawalAll right. Hello, everyone. Good morning. Welcome to day one of the CANTER Global Healthcare Conference. For the first session today, we have AnaptysBio. My name is Prakhara Gurwal. I'm a biotech analyst on CANTER. Joining us from AnaptysBio, we have Dan Faga, President and Chief Executive Officer. Dan, thank you for coming to us.Daniel FagaGood ...

REDWOOD CITY, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Coherus Oncology, Inc. (NASDAQ: CHRS) today announced that the company will be webcasting its participation in the following upcoming conferences: Baird 2025 Global Healthcare Conference in New York, NY on Tuesday, September 9, 2025, at 1:25 p.m. Eastern Daylight Time / 10:25 a.m. Pacific Daylight TimeH.C. Wainwright 27th Annual Global Investment Conference in New York, NY on Wednesday, September 10, 2025, at 11:00 a.m. Eastern Daylight Time / 8:00 a. ...

Media ReleaseCOPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in an outpatient setting Results showed that 92% of patients with R/R DLBCL received the first full dose of epcoritamab monotherapy in an outpatient settingAdverse event profile and efficacy were consistent with previously reported studies in R/R DLBCL patients Data also demonstrated 64.3% overall response rate w ...

WVE-006: RNA editing for AATD Positive RestorAATion-2 clinical data update Investor presentation September 3, 2025 Forward-looking statements This document contains forward-looking statements. All statements other than statements of historical facts contained in this document, including statements regarding possible or assumed future results of operations, preclinical and clinical studies, business strategies, research and development plans, collaborations and partnerships, regulatory activities and timing ...

Company on Friday, August 29, 2025, filed quarterly reports on Form 10-Q for the periods ended March 31, 2025, and June 30, 2025, respectively, in accord with its August 11, 2025 updated Nasdaq compliance plan.Company also announces notification by Nasdaq dated September 2, 2025, that it now complies with Nasdaq Listing Rule 5250(c)(1). FLORHAM PARK, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company focused on addressing age- ...

PiNACLE - H2H will evaluate rondecabtagene autoleucel (ronde-cel) versus investigator’s choice of approved CD19 CAR T-cell therapies in patients with aggressive large B-cell lymphoma receiving treatment in the second line (2L) settingRonde-cel is Lyell’s next-generation, dual-targeting CD19/CD20 CAR T-cell therapy designed to deliver improved complete response rates and longer duration of responses over currently approved CD19 CAR T-cell therapiesSteering Committee of distinguished lymphoma experts establis ...

OS Therapies to Participate in Upcoming Investor Conferences in September 2025September 03, 2025 7:40 AM EDT | Source: OS TherapiesNew York, New York--(Newsfile Corp. - September 3, 2025) - OS Therapies Inc. (NYSE American: OSTX) ("OS Therapies" or "the Company"), a clinical-stage cancer immunotherapy and antibody drug conjugate biotechnology company, today announced that it will participate in the upcoming investor conferences:Cantor Global Healthcare Conference 2025 being held September 3-5, ...

WATERTOWN, Mass., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced the appointment of Brian Adams, JD, as Chief Legal Officer and Corporate Secretary. Mr. Adams is a highly accomplished legal executive with nearly two decades of leadership in the life sciences, spanning corporate development, strategic planning, and governance. He ...

Core Insights - Purple Biotech is advancing the development of a tri-specific antibody targeting TROP2, which is part of its CAPTN-3 platform aimed at overcoming tumor immune evasion and drug resistance [1][2][8] - The company plans to submit an Investigational New Drug (IND) application for its first CAPTN-3 tri-specific antibody, IM1240, in 2026 [1] - Encouraging preclinical results have shown sustained tumor regression in human triple negative breast cancer (TNBC) models, with significant cell death in various tumor types at low doses [4][5] Company Overview - Purple Biotech Ltd. is a clinical-stage company focused on developing first-in-class therapies to combat tumor immune evasion and drug resistance [8] - The company's oncology pipeline includes CAPTN-3, CM24, and NT219, with CAPTN-3 being a preclinical platform of conditionally activated tri-specific antibodies [8][9] - The CAPTN-3 platform utilizes a unique mechanism of action that engages both innate and adaptive immune systems to enhance anti-tumoral responses [8] Technology and Mechanism - The tri-specific antibody IM1305 includes a masked anti-CD3 arm designed to reduce off-target effects while enhancing efficacy in the tumor microenvironment [3][6] - TROP2 is expressed in various solid tumors and is linked to poor prognosis, making it a significant target for therapeutic development [5][6] - The CAPTN-3 platform's ability to recruit multiple immune effectors (T and NK cells) is expected to provide a strong rationale for its effectiveness across diverse tumor types [6][7] Future Prospects - The company is optimistic about the growing interest in TROP2 as a therapeutic target and aims to leverage its technological advancements to accelerate development timelines [7] - Purple Biotech believes that its CAPTN-3 platform can generate multiple programs and expand partnership opportunities in the oncology space [7]

Core Insights - Fractyl Health, Inc. has appointed Christopher Thompson, M.D. and Ian Sheffield as Independent Directors to strengthen its Board of Directors as it advances its product candidates Revita and Rejuva [1][2][5] Company Overview - Fractyl Health is a metabolic therapeutics company focused on innovative treatments for obesity and type 2 diabetes (T2D), aiming to transform disease management from symptomatic to disease-modifying therapies [6] - The company has a robust intellectual property portfolio with 33 granted U.S. patents and approximately 40 pending U.S. applications [6] Product Development - Revita is designed to remodel the duodenal lining to reverse damage caused by high-fat and high-sugar diets, and it has received U.S. FDA Breakthrough Device designation for weight maintenance in patients who discontinue GLP-1 based drugs [7] - The pivotal study REMAIN-1 for Revita has been initiated and completed enrollment [7] - The Rejuva platform focuses on developing AAV-based gene therapies for obesity and T2D, with the first Clinical Trial Application submitted for RJVA-001 [8] Leadership Appointments - Christopher Thompson, M.D. brings extensive experience in bariatric endoscopy and has co-founded several start-ups in endoscopic technology, which aligns with Fractyl's upcoming clinical milestones [2][3] - Ian Sheffield has a 20-year track record in healthcare investing and operations, which will aid Fractyl in navigating late-stage development and strategic partnerships [3][5] Strategic Importance - The appointments of Thompson and Sheffield are seen as timely as the company prepares for key milestones and aims to capture significant clinical and economic opportunities in metabolic care [5]